Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.

In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
Drs. Amy Paller and Lisa Swanson discuss the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth with advanced therapy, especially among children of shorter stature at baseline.
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.
Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.